623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12
F.P. Lin(The University of Sydney), David M. Thomas(New South Wales Department of Health), Rosemary Harrup(University of Tasmania), Harpreet S. Takhar(Kaiser Permanente), J. Lee(Chris O’Brien Lifehouse), B.G.M. Hughes(Royal Brisbane and Women's Hospital), A. Nagrial(Westmead Hospital), B.J. Solomon(Peter MacCallum Cancer Centre), Subotheni Thavaneswaran(The University of Sydney), J. Desai(Peter MacCallum Cancer Centre), A. Mersiades(The University of Sydney), S. Chinchen(The University of Sydney), Chee Khoon Lee(The University of Sydney), W. Xu(Princess Alexandra Hospital), Michael Millward(The University of Western Australia), D. Espinoza(The University of Sydney), Michail Charakidis(Royal Adelaide Hospital), N. Pavlakis(Royal North Shore Hospital), John Simes(The University of Sydney), Craig Underhill(AstraZeneca (United Kingdom))
Cited by 1
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
|Journal of Thoracic Oncology|2016|842
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695